Gabapentin
Product Images NDC 54868-5226

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 54868-5226). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

300 mg Package Label (5166)

Packaging label for Gabapentin capsules 300 mg from Physicians Total Care, Inc. The label indicates a 60 capsule count and includes a caution that federal law prohibits dispensing without a prescription. It also shows lot number, expiration date, storage instructions, usage warnings, and a barcode.*

FDA Label Image

100 mg Package Label (5226)

Gabapentin 100 mg capsules packaging label from Physicians Total Care, Inc. The label includes dosage strength, capsule count (60 capsules), storage instructions, warnings, and barcode. The label also displays the NDC number 54868-5226-2 and lot and expiration date information.*

FDA Label Image

400 mg Package Label (5901)

Gabapentin 400 mg capsules label from Physicians Total Care, Inc. The label indicates 60 capsules per bottle and includes cautionary federal law dispensing restrictions. It provides instructions to use the medication only as directed and warns against refilling without a prescription. Storage directions and barcode are also visible.*

FDA Label Image

D239baac-figure-01 (D239baac Figure 01)

Chemical structure of gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and an acetic acid moiety (CH2CO2H).*

FDA Label Image

D239baac-figure-02 (D239baac Figure 02)

A line graph displaying mean pain scores over an 8-week period comparing placebo and Gabapentin, 3600 mg/day. The timeline is divided into a 4-week dose titration period and a 4-week fixed dose period. Gabapentin shows a decrease in pain scores over time, while placebo scores remain relatively stable. Statistical significance is indicated at various points.*

FDA Label Image

D239baac-figure-03 (D239baac Figure 03)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period, with both Gabapentin doses showing significant reductions in pain scores compared to placebo.*

FDA Label Image

D239baac-figure-04 (D239baac Figure 04)

A bar graph depicting the percentage of responders at endpoint for a clinical study comparing placebo (PBO) with Gabapentin (GBP) at different dosages across two studies. Study 1 compares PBO to GBP 3600 mg, showing 12% versus 29% responders. Study 2 compares PBO to GBP 1800 mg and 2400 mg, showing 14%, 32%, and 34% responders respectively. Statistical significance markers indicate p-values less than 0.01 and 0.001 for the Gabapentin groups versus placebo.*

FDA Label Image

D239baac-figure-05 (D239baac Figure 05)

A scatter plot comparing differences (%) across daily doses (mg) of gabapentin from three studies labeled a, b, and c. The x-axis shows daily doses at approximately 600, 900, 1200, and 1800 mg, while the y-axis shows percentage difference ranging from 2% to 22%. Different colored squares represent the three studies, with labels a, b, and c indicating data points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.